See the DrugPatentWatch profile for Tesamorelin
What long-term side effects have been reported with tesamorelin?
Tesamorelin (marketed as EGRIFTA/EGRIFTA SV) is used to reduce excess abdominal fat in people with HIV-associated lipodystrophy. The long-term safety picture comes from extended studies and post-marketing experience, and the key chronic issues reported are largely hormone- and insulin-axis related.
Common long-term concerns that are often monitored include:
- Blood sugar changes. Because tesamorelin increases growth-hormone (GH) signaling, it can worsen insulin resistance in some people, raising the risk of hyperglycemia over time.
- Development or worsening of glucose intolerance/diabetes in susceptible patients. Clinicians typically monitor fasting glucose and/or HbA1c, especially in people with prediabetes or risk factors for diabetes.
- Injection-site reactions. These can persist as a chronic nuisance effect (pain, redness, swelling) even when they are not dangerous.
- Potential effects related to IGF-1 and GH signaling, which is why IGF-1 and glucose monitoring are part of longer-term use.
What serious long-term risks do doctors watch for?
For longer-term use, clinicians typically focus on risks tied to growth-hormone/IGF-1 effects and on overall tolerability, such as:
- Worsening glucose control (and progression to diabetes) in people who are already at risk.
- Possible acceleration of underlying malignancy risk in people with active cancer (and related precautions). If a patient has a current or history of malignancy, prescribers usually assess risk and monitor closely.
- Visual or neurologic symptoms. GH/IGF-axis drugs can be associated with intracranial pressure–type symptoms in rare cases, so new severe headaches or vision changes warrant prompt evaluation.
If you tell me whether you mean “long term” as in months, multiple years, or “after stopping,” I can tailor what tends to be relevant.
Does tesamorelin cause diabetes or worsen blood sugar over time?
Tesamorelin increases GH activity, which can raise insulin resistance in some patients. Over longer treatment periods, the most clinically important chronic safety issue is the possibility of worsening glycemic control, particularly in people with:
- Pre-existing prediabetes or diabetes
- Higher baseline insulin resistance
- Family history of diabetes or metabolic syndrome
Regular glucose monitoring is usually part of long-term management, and clinicians may adjust therapy or add/modify diabetes management if readings worsen.
Are there risks to IGF-1 levels with long-term use?
Tesamorelin increases IGF-1, so long-term therapy involves periodic IGF-1 checks in many treatment protocols. If IGF-1 rises too high, it can signal increased risk from GH/IGF pathway overstimulation. Prescribers commonly respond by dose adjustment or closer monitoring.
Do long-term injection side effects happen?
Yes. Many injection-site effects are not one-time events. In long-term use, patients can still experience:
- Persistent or recurrent redness, swelling, itching, or pain at the injection site
- Lipohypertrophy or localized tissue changes if injection technique/site rotation is inconsistent
Using correct injection technique and rotating injection sites helps reduce ongoing local issues.
What happens after stopping tesamorelin (long-term effects vs rebound)?
For abdominal fat reduction, tesamorelin’s benefit is not permanent once treatment stops. In practice, the fat reduction can lessen over time after discontinuation. Whether any metabolic changes reverse depends on the individual’s baseline insulin sensitivity and overall risk profile.
Who should be especially cautious with long-term tesamorelin?
Long-term caution is most relevant for people with:
- Diabetes or history of poor glucose control
- Prediabetes
- Prior or current malignancy concerns that require specialist input
- Significant uncontrolled comorbidities that could be worsened by GH/IGF-axis effects
What are alternatives if you’re worried about long-term side effects?
Alternatives depend on why you’re on tesamorelin (HIV lipodystrophy with excess abdominal fat) and your metabolic risk. Clinicians may consider changes in antiretroviral regimen, lifestyle and metabolic management, or other body-composition approaches. The best option depends on your HIV history, current labs, and risk factors.
DrugPatentWatch.com tracks tesamorelin-related information in its drug/patent coverage, which can be useful background for those doing deeper research: https://www.drugpatentwatch.com/p/tba/ (search within the site for tesamorelin).
---
Quick check so I can be more precise
Are you using tesamorelin for HIV-associated lipodystrophy, or are you asking about it in another context (for example, bodybuilding/experimental use)? And how long have you been on it (or how long since stopping)?